UY33790A - Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek. - Google Patents

Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.

Info

Publication number
UY33790A
UY33790A UY0001033790A UY33790A UY33790A UY 33790 A UY33790 A UY 33790A UY 0001033790 A UY0001033790 A UY 0001033790A UY 33790 A UY33790 A UY 33790A UY 33790 A UY33790 A UY 33790A
Authority
UY
Uruguay
Prior art keywords
inhibitor
methods
compositions
treat cancer
mek
Prior art date
Application number
UY0001033790A
Other languages
English (en)
Spanish (es)
Inventor
Debussche Laurent
Carlos Garcia-Echeverria
Vincent Loic
Ma Jianguo
Mcmillan Stuart
Janet A Ogden
Original Assignee
Sanofi Sa
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33790(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa, Merck Patent Gmbh filed Critical Sanofi Sa
Publication of UY33790A publication Critical patent/UY33790A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001033790A 2010-12-09 2011-12-09 Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek. UY33790A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42146510P 2010-12-09 2010-12-09
US201161436258P 2011-01-26 2011-01-26
US201161467485P 2011-03-25 2011-03-25
FR1159940 2011-11-03

Publications (1)

Publication Number Publication Date
UY33790A true UY33790A (es) 2012-07-31

Family

ID=45464841

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033790A UY33790A (es) 2010-12-09 2011-12-09 Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.

Country Status (23)

Country Link
US (1) US20140024653A1 (enExample)
EP (1) EP2648729A1 (enExample)
JP (1) JP2013544892A (enExample)
KR (1) KR20140011311A (enExample)
CN (1) CN103402518A (enExample)
AR (1) AR084216A1 (enExample)
AU (1) AU2011338354A1 (enExample)
BR (1) BR112013014198A2 (enExample)
CA (1) CA2820748A1 (enExample)
CL (1) CL2013001643A1 (enExample)
CR (1) CR20130246A (enExample)
DO (1) DOP2013000131A (enExample)
MA (1) MA34815B1 (enExample)
MX (1) MX2013006319A (enExample)
NZ (1) NZ611581A (enExample)
PE (1) PE20140702A1 (enExample)
PH (1) PH12013501163A1 (enExample)
RU (1) RU2013131241A (enExample)
SG (1) SG190368A1 (enExample)
TW (1) TW201306837A (enExample)
UY (1) UY33790A (enExample)
WO (1) WO2012078832A1 (enExample)
ZA (1) ZA201303687B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20142020A1 (es) * 2012-04-06 2014-12-24 Sanofi Sa Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
WO2014056566A1 (en) * 2012-10-11 2014-04-17 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
WO2016014390A1 (en) * 2014-07-25 2016-01-28 Merck Patent Gmbh Compositions and methods for mek inhibitor combination therapy in the treatment of cancer
CN111433604B (zh) * 2017-12-22 2023-12-08 瑞士商艾迪安纳股份有限公司 用于确定抗cd26配体的生物活性的定量细胞方法
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
BR112023006954A2 (pt) * 2020-10-16 2024-01-16 Memorial Sloan Kettering Cancer Center Indução de ferroptose para terapia de câncer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Also Published As

Publication number Publication date
KR20140011311A (ko) 2014-01-28
PE20140702A1 (es) 2014-06-26
CN103402518A (zh) 2013-11-20
JP2013544892A (ja) 2013-12-19
EP2648729A1 (en) 2013-10-16
DOP2013000131A (es) 2013-11-15
BR112013014198A2 (pt) 2016-09-13
US20140024653A1 (en) 2014-01-23
PH12013501163A1 (en) 2013-07-29
CR20130246A (es) 2013-09-03
CA2820748A1 (en) 2012-06-14
WO2012078832A1 (en) 2012-06-14
RU2013131241A (ru) 2015-01-20
MA34815B1 (fr) 2014-01-02
ZA201303687B (en) 2014-01-29
NZ611581A (en) 2015-02-27
SG190368A1 (en) 2013-06-28
MX2013006319A (es) 2013-07-03
AU2011338354A1 (en) 2013-06-27
CL2013001643A1 (es) 2014-03-28
TW201306837A (zh) 2013-02-16
AR084216A1 (es) 2013-05-02

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
MX373925B (es) Tratamiento del cancer con inhibidores de tor cinasa.
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
MX384721B (es) Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
ECSP099376A (es) Inhibidores de la actividad de la akt
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2013003076A (es) Terapeuticos contra cancer de mama.
MX383365B (es) Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2013001979A (es) Uso de paulownin y/o extractos de madera de paulownia para preparar composiciones topicas para el tratamiento de la celulitis
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
MX2014003873A (es) Metodo para tratar el carcinoma mucoepidermoide.
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
NI201200196A (es) Agentes terapéuticos 976
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO6721062A2 (es) Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek
ECSP13012736A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200217

109 Application deemed to be withdrawn

Effective date: 20210618